Profile of Robert James
Rob has been involved in the exploitation of early stage intellectual property for 20 years since he completed his PhD in Biochemistry in 1990. Rob worked for Cancer Research Campaign Technology for seven years before moving to Prelude Ventures, one of Europe’s oldest early stage venture capital investors. He was a Founding Partner of DFJ Esprit. Rob has been involved in many technologies and businesses which in aggregate have raised well over £200m in financing. Notable achievements have been: involvement in licensing Temodal to Schering Plough prior to it becoming a billion dollar cancer drug, financing a new method to purify DNA and RNA called Charge Switch Technology, which is now globally available via Life Technologies and financing the global launch of a new diagnostic product for latent TB via Oxford Immunotec which is now a NASDAQ quoted company. Rob founded Sixth Element Capital (6EC) with his partners Ian Miscampbell and Ralph Villiger as a Fund Manager designed to find innovative ways to invest in biotechnology. The CRT Pioneer Fund is 6EC’s first fund.